cell signaling technology 5605 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
96
Structured Review
Cell Signaling Technology Inc
cell signaling technology 5605
Cell Signaling Technology 5605, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1608 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+5605/c-Myc+Rabbit+mAb/pm41855638-249-31-31
Average 96 stars, based on 1608 article reviews
Cell Signaling Technology 5605, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1608 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+5605/c-Myc+Rabbit+mAb/pm41855638-249-31-31
Average 96 stars, based on 1608 article reviews
cell signaling technology 5605 - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
other:Article Title: Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer Article Snippet: Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients.. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential.. Therefore, strategies targeting such persister cells may prevent recurrent disease. Article Title: Cathepsin E drives colorectal cancer progression and immune evasion via ZNF326 ADP-ribosylation and TGF-β/SMAD activation. Article Snippet: The primary antibodies used include PAR/pADPr antibody (R&D, 4335-MC-100), Myc antibody ( Article Title: FBXW7 Targets the SPT6‐ΔNp63 Axis for Degradation to Inhibit Esophageal Tumorigenesis Induced by 4‐Nitroquinoline N‐Oxide Article Snippet: Antibodies were used as follows: FBXW7 (Bethyl, A301‐720A and A301‐721A), SPT6 (Santa Cruz, sc‐393920, and Novus, NB100‐2582), RBM7 (Proteintech, 21896‐1‐AP), LSM14A (Proteintech, 18336‐1‐AP), UAP1L1 (Proteintech, 25262‐1‐AP), WASHC4 (Proteintech, 51101‐1‐AP), PLEKHF2 (Proteintech, 25424‐1‐AP), PDPK1 (Proteintech, 17086‐1‐AP), EI24 (Proteintech, 20456‐1‐AP), NEDD8 (Abcam, ab81264), Article Title: Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity Article Snippet: Various primary antibodies were used to detect Article Title: Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity. Article Snippet: Various primary antibodies were used to detect Article Title: Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer. Article Snippet: The primary antibodies used in this study were as follows: Cyclin B1 (Proteintech, 55004-1-AP), Cyclin E1 (Proteintech, 11554-1-AP), Cyclin D1 (Proteintech, 60186-1-Ig), CDK2 (Proteintech, 60312-1-Ig), GAPDH (Proteintech, HRP-60004), Mcl-1 (Proteintech, 16225-1-AP), Bcl-2 (Proteintech, 12789-1-AP), Bax (ABclonal, A19684), Bid (ABclonal, A23234), Incubation:Article Title: Supinoxin Blocks Small Cell Lung Cancer Progression by Inhibiting Mitochondrial Respiration through DDX5 Article Snippet: 20–50 mg of total protein was loaded onto an 8% SDS-PAGE gel, which was then electrophoresed and transferred to nitrocellulose membrane using the Mini PROTEAN Tetra Cell device (Bio-Rad). .. After being blocked in 2% skimmed milk for 5 min, membranes were incubated at 4 C overnight with primary antibodies b-catenin (Invitrogen, 13–8400), DDX5 (Abcam, ab126730), RFC1 (Abcam, ab3853), phosphor-DDX5 (Y593) (Abcam, ab62255), c-Myc ( Western Blot:Article Title: Gossypol suppresses tumorigenesis through inhibition of multiple deubiquitinating enzymes. Article Snippet: Gossypol is a polyphenolic compound recognized for its role as a Bcl-2 family protein inhibitor, attracting considerable interest mainly due to its antitumor properties.. However, its development as a therapeutic agent has faced hurdles from off-target side effects, partially stemming from an incomplete understanding of its target profile.. In this study, we identified Gossypol as a multi-deubiquitinating enzyme (DUB) inhibitor, exhibiting preference for the ubiquitin-specific protease (USP) subfamily members. |